Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs.
Amy K LeBlancChristina N MazckoAswini CherukuriErika P BergerWilliam C KisseberthMegan E BrownSusan E LanaKristen WeishaarBrian K FlesnerJeffrey N BryanDavid M VailJenna H BurtonJennifer L WillcoxAnthony J MutsaersJ Paul WoodsNicole C NorthrupCorey SabaKaitlin M CurranHaley J LeeperHeather Wilson-RoblesBrandan Wustefeld JanssensStephanie LindleyAnnette N SmithNikolaos DervisisShawna KlahnMary Lynn HigginbothamRaelene M WoudaErika KrickJennifer A MahoneyCheryl A LondonLisa G BarberCheryl E BalkmanAngela L McCleary-WheelerSteven E SuterOlya MartinAntonella BorgattiKristine E BurgessMichael O ChildressJanean L FidelSara D AllstadtDaniel L GustafsonLaura E SelmicChand KhannaTimothy M FanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In a population of pet dogs nongenomically segmented for predicted mTOR inhibition response, sequentially administered adjuvant sirolimus, although well tolerated when added to a backbone of therapy, did not extend DFI or survival in dogs with appendicular osteosarcoma.